Outcomes of patients not achieving primary endpoint from an ibalizumab Phase III trial

被引：0
|
作者：
DeJesus, E. [1 ]
Emu, B. [2 ]
Weinheimer, S. [3 ]
Cohen, Z. [4 ]
Cash, B. [5 ]
Lewis, S. [3 ]
机构：
[1] Orlando Immunol Ctr, Infect Dis, Orlando, FL USA
[2] Yale Sch Med, Infect Dis, New Haven, CT USA
[3] TaiMed Biol, HIV, Irvine, CA USA
[4] Theratechnologies, HIV, Montreal, PQ, Canada
[5] Syneos Hlth, HIV, Somerset, NJ USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P064
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Analysis of patients completing the ibalizumab Phase III trial and expanded access program
    Emu, B.
    Weinheimer, S.
    Cohen, Z.
    Lewis, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [2] Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from US Cooperative Oncology Groups
    Schroen, Anneke T.
    Petroni, Gina R.
    Wang, Hongkun
    Thielen, Monika J.
    Gray, Robert
    Benedetti, Jacqueline
    Wang, Xiaofei F.
    Sargent, Daniel J.
    Wickerham, Donald L.
    Cronin, Walter
    Djulbegovic, Benjamin
    Slingluff, Craig L., Jr.
    CLINICAL CANCER RESEARCH, 2012, 18 (01) : 256 - 262
  • [3] Should MRI be the primary endpoint of phase III trials in MS? No
    Weinshenker, B. G.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 28 - 28
  • [4] Risk reduction with obeticholic acid in patients not achieving the POISE primary endpoint
    Harms, M.
    Carbone, M.
    Hansen, B.
    Mells, G.
    Pencek, R.
    Smoot-Malecha, E.
    MacConell, L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S548 - S548
  • [5] Outcomes for patients with advanced GIST achieving a complete remission (CR) with imatinib (IM): Results from the prospective randomized phase III trial of the French Sarcoma Group
    Cioffi, A., Jr.
    Dufresne, A.
    Italiano, A.
    Rios, M.
    Blesius, A.
    Bertucci, F.
    Adenis, A.
    Darnis, S.
    Le Cesne, A.
    Blay, J. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Saxagliptin meets primary safety endpoint in large, phase IV trial
    Reactions Weekly, 2013, 1459 (1) : 2 - 2
  • [7] Phase II trial design with growth modulation index as the primary endpoint
    Wu, Jianrong
    Chen, Li
    Wei, Jing
    Weiss, Heidi
    Miller, Rachel W.
    Villano, John L.
    PHARMACEUTICAL STATISTICS, 2019, 18 (02) : 212 - 222
  • [8] Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
    Wolinsky, Jerry S.
    Narayana, Ponnada A.
    Nelson, Flavia
    Datta, Sushmita
    O'Connor, Paul
    Confavreux, Christian
    Comi, Giancarlo
    Kappos, Ludwig
    Olsson, Tomas P.
    Truffinet, Philippe
    Wang, Lin
    Miller, Aaron
    Freedman, Mark S.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) : 1310 - 1319
  • [9] Phase III study of ETEC vaccine does not meet primary clinical endpoint
    不详
    DRUG NEWS & PERSPECTIVES, 2000, 13 (02) : 114 - 114
  • [10] Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial
    Metzger Filho, O.
    Cardoso, F.
    Poncet, C.
    Desmedt, C.
    Linn, S.
    Wesseling, J.
    Hilbers, F.
    Delaloge, S.
    Pierga, J. -y.
    Brain, E.
    Vrijaldenhoven, S.
    Neijenhuis, P. A.
    Rutgers, E. J. Th
    Piccart, M.
    van't Veer, L. J.
    Viale, G.
    EUROPEAN JOURNAL OF CANCER, 2025, 217
12345